A homocysteine ​​detection kit with good stability and preparation method

By adjusting and combining a variety of raw materials, a homocysteine ​​detection kit is formed with good stability, which solves the problem of long-term unstable existing kits, achieves more accurate and reliable detection results, and is available at different temperatures Excellent stability under conditions.

CN114689415BActive Publication Date: 2024-12-03URIT MEDICAL ELECTRONICS CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202011624844.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-12-31
Publication Date
2024-12-03
Estimated Expiration
2040-12-31

AI Technical Summary

Technical Problem

The existing homocysteine ​​detection kits have long-term instability, which affects the accuracy and reliability of the test results.

Method used

By adjusting the pH of various raw materials and stirring, standing and filtration, an appropriate amount of buffer system, preservative, reducing agent and stabilizer are added to form two reagents, combining cystsulfide β-synthetase and cystsulfide β-synthetase and cystsulfide β - Lyase, use activator to prolong the stability of the reagent.

Benefits of technology

It significantly improves the long-term stability of homocysteine ​​detection kits, ensures the accuracy and reliability of the test results, can replace commercially available kits, and exhibits good stability under high and low temperature conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114689415B_ABST
    Figure CN114689415B_ABST
Patent Text Reader

Abstract

The invention discloses a homocysteine ​​detection kit with good stability and a preparation method. According to a ratio requirement, 100 mmol / L of a buffer system, a preservative and 0.01-0.06 g / L of serine are added into a mixing container, and the pH value is adjusted to 9.0±0.2, and after adding 10-100 mmol / L of a reducing agent, stirring, standing and filtering, a corresponding second raw material is added for stirring to obtain a first reagent; according to a ratio requirement, the pH value of the obtained buffer system 50 mmol / L, a stabilizer 1-100 g / L and a preservative is adjusted to 7.6±0.2, and a corresponding fourth raw material is added for mixing to obtain a second reagent, thereby improving the long-term stability of the kit.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical detection, and in particular to a homocysteine ​​detection kit with good stability and a preparation method thereof. Background Art

[0002] Homocysteine ​​(HCY) is a sulfur-containing amino acid that does not directly participate in human protein synthesis and is an intermediate product of human metabolism. Currently, there are many methods for detecting homocysteine, including high performance liquid chromatography (HPLC), fluorescence polarization immunoassay (FPIA), enzyme-linked immunosorbent assay (ELISA), amino acid analysis, ion chromatography, electrochemistry, enzyme cycling, etc.

[0003] Clinically, the enzyme cycle method is one of the mainstream methods for detecting homocysteine. The detection principle is that homocysteine ​​reacts with serine under the catalysis of cystathionine β-synthase to produce L-cystathionine, and L-cystathionine is generated by cystathionine β-lyase to generate homocysteine, pyruvate and ammonia. The pyruvate generated by this cycle reaction can be detected by lactate dehydrogenase (LDH) and reduced coenzyme I (NADH). The rate of NADH conversion to NAD+ is proportional to the content of homocysteine. The homocysteine ​​content can be obtained by measuring the rate of NADH reduction. At present, conventional enzyme cycle kits generally have the phenomenon of long-term reagent instability. Summary of the invention

[0004] The purpose of the present invention is to provide a homocysteine ​​detection kit with good stability and a preparation method thereof, so as to improve the long-term stability of the kit.

[0005] To achieve the above object, in a first aspect, the present invention provides a method for preparing a homocysteine ​​detection kit with good stability, comprising the following steps:

[0006] The pH of the obtained multiple first raw materials is adjusted, and after stirring, standing and filtering, the corresponding second raw materials are added and stirred to obtain a first reagent;

[0007] The pH values ​​of the obtained third raw materials are adjusted to 7.6±0.2, and the corresponding fourth raw materials are added and mixed to obtain the second reagent.

[0008] The pH of the obtained multiple first raw materials is adjusted, and after stirring, standing and filtering, the corresponding second raw materials are added and stirred to obtain the first reagent, including:

[0009] According to the ratio requirements, 100mmol / L of buffer system, preservative and 0.01-0.06g / L of serine were added into the mixing container, and the pH value was adjusted to 9.0±0.2;

[0010] Adding 10-100 mmol / L of a reducing agent into the mixing container;

[0011] After stirring, standing and filtering, the corresponding second raw material is added and stirred to obtain the first reagent.

[0012] After stirring, standing and filtering, adding the corresponding second raw material and stirring to obtain the first reagent, comprising:

[0013] Stirring the mixing container at a set stirring time and stirring speed;

[0014] After the stirring is completed, the mixing container is placed at 2-8 degrees for equilibration for 24 hours, and filtered using a stainless steel filter and a filter membrane;

[0015] The second raw material is added to the filtered mixing container, and stirred to obtain the first reagent.

[0016] In a second aspect, the present invention provides a homocysteine ​​detection kit with good stability, wherein the preparation method of a homocysteine ​​detection kit with good stability as described in the first aspect is applied to a homocysteine ​​detection kit with good stability,

[0017] The homocysteine ​​detection kit with good stability comprises a first reagent and a second reagent, wherein the first reagent comprises a first raw material and a second raw material, and the second reagent comprises a third raw material and a third raw material;

[0018] The first raw material includes a buffer system of 100 mmol / L, a preservative and serine of 0.01-0.06 g / L, and a reducing agent of 10-100 mmol / L; the second raw material includes NADH of 0.1-0.5 g / L and LDH of 10-50 ku / L;

[0019] The third raw material includes a buffer system of 50 mmol / L, a stabilizer of 1-100 g / L and a preservative; the fourth raw material includes cystathionine β-synthase of 1-10 KU / L, cystathionine β-lyase of 1-10 KU / L and an activator of 0.001-0.01 g / L.

[0020] Wherein, the reducing agent is one or more of TCEP, GPC, and EGTA, wherein the TCEP, the GPC, and the one or more of EGTA are mixed at a molar concentration ratio of 1:0.8-1.2:2-2.5.

[0021] Wherein, the stabilizer is one or more of ethylene glycol, β-methyl dextrin, dextran 70, D-trehalose, and PEG6000.

[0022] Wherein, the buffer system is one or more of HEPES, triethanolamine, TRIS-HCL, and TES.

[0023] The invention discloses a homocysteine ​​detection kit with good stability and a preparation method thereof. According to the ratio requirement, 100 mmol / L of a buffer system, a preservative and 0.01-0.06 g / L of serine are added into a mixing container, and the pH value is adjusted to 9.0±0.2. After adding 10-100 mmol / L of a reducing agent, stirring, standing and filtering, a corresponding second raw material is added for stirring to obtain a first reagent. According to the ratio requirement, the pH value of the obtained buffer system of 50 mmol / L, a stabilizer of 1-100 g / L and a preservative is adjusted to 7.6±0.2, and a corresponding fourth raw material is added for mixing to obtain a second reagent, thereby improving the long-term stability of the kit. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 The present invention is a schematic diagram of the steps of preparing a homocysteine ​​detection kit with good stability.

[0026] Figure 2 The present invention provides a homocysteine ​​detection kit with good stability, and compares the clinical relevance with an imported kit.

[0027] Figure 3 The present invention provides a homocysteine ​​detection kit with good stability and a long-term monitoring curve diagram of the quality control product of the comparison kit.

[0028] Figure 4 The present invention provides a thermal stability curve diagram of a homocysteine ​​detection kit and a comparison kit with good stability. DETAILED DESCRIPTION

[0029] Embodiments of the present invention are described in detail below, examples of which are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limiting the present invention.

[0030] In the description of the present invention, “plurality” means two or more than two, unless otherwise clearly and specifically defined.

[0031] See also Figure 1 The present invention provides a method for preparing a homocysteine ​​detection kit with good stability, comprising the following steps:

[0032] S101, adjusting the pH of the obtained plurality of first raw materials, and after stirring, standing and filtering, adding the corresponding second raw materials and stirring to obtain a first reagent.

[0033] Specifically, according to the ratio requirements, 100mmol / L of buffer system, preservative and 0.01-0.06g / L of serine are added to a mixing container, and the pH value is adjusted to 9.0±0.2; 10-100mmol / L of reducing agent is added to the mixing container; the mixing container is stirred at a set stirring time and stirring speed; then, the mixing container after stirring is placed at 2-8 degrees for at least 24h, and filtered using a stainless steel filter and a filter membrane, and finally NADH0.1-0.5g / L and LDH 10-50ku / L are added to the filtered mixing container for stirring and mixing to obtain the first reagent, wherein the reducing agent is a mixture of TCEP, GPC, and EGTA. The reducing agent combination of the present invention is more stable than others and has a wider pH range.

[0034] The above reducing agent mixture is mixed at a molar concentration ratio of 1:0.8-1.2:2-2.5. The reducing agent concentration is specified to be below 10-100mmol / L because during the detection process, the theoretical reducing agent concentration required for the oxidation of HCY reduced form should not be too high. Too high a reducing agent will affect subsequent reactions and thus affect the clinical test results. Too low a reducing agent concentration will lead to insufficient oxidation and low clinical tests. The reducing agent concentration described in the present invention refers to the TCEP concentration, and the GPC and EGTA concentrations are more stable when mixed with TCEP according to the above ratio.

[0035] S102, adjusting the pH values ​​of the obtained plurality of third raw materials to 7.6±0.2, and adding the corresponding fourth raw materials to mix, so as to obtain a second reagent.

[0036] Specifically, according to the formula requirements, a buffer system of 50mmol / L, a stabilizer of 1-100g / L, and a preservative are added to another mixing container in sequence, and the pH value is adjusted to 7.60±0.20, and cystathionine β-synthase 1-10KU / L, cystathionine β-lyase 1-10KU / L, and an activator of 0.001-0.01g / L are added in sequence to obtain a second reagent. The activator is pyridoxal 5-phosphate, and the rational use of the activator can effectively reduce the concentration of cystathionine β-synthase / lyase and reduce costs; the activator and the stabilizer can effectively improve the activity reduction of cystathionine β-synthase / lyase over time, and effectively extend the long-term stability of the reagent.

[0037] The present invention provides a homocysteine ​​detection kit with good stability. The preparation method of the homocysteine ​​detection kit with good stability is applied to a homocysteine ​​detection kit with good stability. The homocysteine ​​detection kit with good stability comprises a first reagent and a second reagent, the first reagent comprises a first raw material and a second raw material, and the second reagent comprises a third raw material and a third raw material;

[0038] The first raw material includes a buffer system of 100 mmol / L, a preservative and serine of 0.01-0.06 g / L, and a reducing agent of 10-100 mmol / L; the second raw material includes NADH of 0.1-0.5 g / L and LDH of 10-50 ku / L;

[0039] The third raw material includes a buffer system of 50 mmol / L, a stabilizer of 1-100 g / L and a preservative; the fourth raw material includes cystathionine β-synthase of 1-10 KU / L, cystathionine β-lyase of 1-10 KU / L and an activator of 0.001-0.01 g / L.

[0040] In this embodiment, the reducing agent is one or more of TCEP, GPC, and EGTA, wherein the TCEP, the GPC, and the EGTA are mixed at a molar concentration ratio of 1:0.8-1.2:2-2.5. The stabilizer is one or more of ethylene glycol, β-methyl dextrin, dextran 70, D-trehalose, and PEG6000. The buffer system is one or more of HEPES, triethanolamine, TRIS-HCL, and TES.

[0041] Example 1

[0042] A homocysteine ​​detection kit with good stability comprises a reagent 1 and a reagent 2. The components of the reagent 1 are triethanolamine: 100mmol / L, sodium azide: 1g / L, TCEP: 50mmol / L, GPC: 40mmol / L, EGTA: 100mmol / L: serine: 0.05g / L, NADH: 0.3g / L, LDH: 30KU / L, and Brj-35: 2g / L; the components of the reagent 2 are triethanolamine: 50mmol / L, ethylene glycol: 100g / L, 5-pyridoxal phosphate: 0.008g / L, cystathionine β-synthase: 5KU / L, and cystathionine β-lyase: 5KU / L.

[0043] Example 2

[0044] A homocysteine ​​detection kit with good stability comprises a reagent 1 and a reagent 2, wherein the components of the reagent 1 are triethanolamine: 100mmol / L, sodium azide: 1g / L, TCEP: 100mmol / L, GPC: 80mmol / L, EGTA: 200mmol / L: serine: 0.06g / L, NADH: 0.5g / L, LDH: 50KU / L, and Brj-35: 2.5g / L; and the components of the reagent 2 are triethanolamine: 50mmol / L, ethylene glycol: 80g / L, 5-pyridoxal phosphate: 0.01g / L, cystathionine β-synthase: 10KU / L, and cystathionine β-lyase: 10KU / L.

[0045] Example 3

[0046] A homocysteine ​​detection kit with good stability comprises a reagent 1 and a reagent 2, wherein the components of the reagent 1 are triethanolamine: 100mmol / L, sodium azide: 1g / L, TCEP: 20mmol / L, GPC: 10mmol / L, EGTA: 25mmol / L: serine: 0.01g / L, NADH: 0.1g / L, LDH: 10KU / L, and Brj-35: 2g / L; and the components of the reagent 2 are triethanolamine: 50mmol / L, ethylene glycol: 100g / L, pyridoxal-5-phosphate: 0.001g / L, cystathionine β-synthase: 2KU / L, and cystathionine β-lyase: 2KU / L.

[0047] Comparative Example 1

[0048] Commercially available imported homocysteine ​​detection kit

[0049] Comparative Example 2

[0050] Commercially available common domestic homocysteine ​​detection kit

[0051] Comparative Example 3

[0052] Compared with the example, the reducing agent is a single TCEP: 50mmol / L.

[0053] Comparative Example 4

[0054] Compared with the example, the reducing agent is a mixture of TCEP and EDTA, which are TCEP: 50mmol / L, and EDTA: 10mmol / L.

[0055] Comparative Example 5

[0056] Compared with the example, the reducing agent is a mixture of TCEP, thioglycolic acid and EDTA, which are: TCEP: 50mmol / L, thioglycolic acid: 10mmol / L, EDTA: 10mmol / L.

[0057] Comparative Example 6

[0058] Compared with the example, the reducing agent is a mixture of TCEP, DTT and mercaptoethanol, and the concentration of the composite reducing agent is 20 mmol / L.

[0059] The homocysteine ​​content in 40 clinical serum samples was tested simultaneously with Example 1 of the present invention (or other embodiments of the present invention) and Comparative Example 1. The test results are shown in Table 1. Then, regression analysis was performed with the test results of Comparative Example 1 as the ordinate and the test results of Example 1 as the abscissa. The correlation between the two is shown in Table 1. Figure 2 shown.

[0060] Table 1 Clinical correlation between Example 1 and Comparative Example 1

[0061]

[0062] From Table 1 and Figure 1 It can be seen that the linear correlation coefficient of serum test of Example 1 and Comparative Example 1 kit is: 0.9983, regression equation: Y=0.996x-0.0175, R2=0.997, and the linear relationship is good, indicating that the kit of Example 1 of the present invention has a strong correlation with the imported comparative example kit, indicating that the kit of the present invention can replace the conventional kit available on the market.

[0063] The Example 1 of the present invention (or other embodiments of the present invention) and the comparative examples 2-6 were simultaneously subjected to 2-8 degrees long-term stability monitoring, and the quality control test conditions were monitored every month. The quality control test values ​​are shown in Table 2, and the long-term test curves are shown in Table 2. Figure 3 shown.

[0064] Table 2 Long-term stability quality control test results of Example 1 and Comparative Examples 2-6

[0065] Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 1 10 10.2 10.1 9.8 9.8 9.8 2 9.8 10.1 9.9 9.7 9.6 10 3 10.1 9.8 9.8 9.9 9.8 10.2 4 9.7 9.7 10.2 10.1 9.8 9.6 5 9.9 9.9 10.0 9.6 9.7 9.8 6 10.2 9.4 9.8 9.7 9.6 10.2 7 9.8 7.4 9.2 9.8 9.9 9.8 8 9.6 6.3 8.5 9.3 9.6 9.7 9 9.7 5.4 7.4 9.2 9.5 9.2 10 9.7 4.5 6.5 8.2 8.7 8.9 11 9.8 3.6 5.8 7.8 8.2 8.6 12 9.8 3.0 4.7 7.3 8.1 8.4 13 9.7 2.8 4.2 6.9 7.8 7.6 14 9.6 2.0 3.0 6.5 7.2 7.1

[0066] From Table 2 and Figure 3 It can be seen that the long-term stability of the detection kit of the present invention is significantly better than that of other commercially available detection reagents.

[0067] The detection kit of Example 1 of the present invention (or other embodiments of the present invention) and the detection kits of Comparative Examples 2-6 were simultaneously subjected to 37°C load stability monitoring, and quality control changes were monitored every day. The daily quality control change data are shown in Table 3, and the stability curves are shown in Table 3. Figure 4 .

[0068] Table 3 Thermal stability quality control test data of Example 1 and Comparative Examples 2-6

[0069] Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 1 10 9.8 9.9 9.8 9.8 9.8 2 9.8 9.7 10.1 9.9 9.6 10 3 10.1 9.6 9.8 9.7 9.8 10.2 4 9.7 9.5 9.6 9.6 9.8 9.6 5 9.9 9.3 9.4 9.3 9.7 9.8 6 10.2 9.4 9.2 9.4 9.6 10.2 7 9.8 8.6 9.5 9.6 9.5 9.8

[0070] From Table 3 and Figure 4 It can be seen that there is no obvious difference in thermal stability between the detection kit of the present invention and other commercially available detection kits.

[0071] The present invention provides a method for detecting homocysteine ​​in serum: method: rate method, main / sub wavelength: 340nm / 405nm, sample / reagent 1 / reagent 2: 13 / 240 / 65, calibration method: two-point calibration, reaction direction: negative reaction. The specific implementation is shown in Table 4 below.

[0072] Table 4 Homocysteine ​​detection reagent detection method

[0073]

[0074] The invention discloses a homocysteine ​​detection kit with good stability and a preparation method thereof. According to the ratio requirement, 100 mmol / L of a buffer system, a preservative and 0.01-0.06 g / L of serine are added into a mixing container, and the pH value is adjusted to 9.0±0.2. After adding 10-100 mmol / L of a reducing agent, stirring, standing and filtering, a corresponding second raw material is added for stirring to obtain a first reagent. According to the ratio requirement, the pH value of the obtained buffer system of 50 mmol / L, a stabilizer of 1-100 g / L and a preservative is adjusted to 7.6±0.2, and a corresponding fourth raw material is added for mixing to obtain a second reagent, thereby improving the long-term stability of the kit.

[0075] What is disclosed above is only a preferred embodiment of the present invention, and it certainly cannot be used to limit the scope of rights of the present invention. Ordinary technicians in this field can understand that all or part of the processes of the above embodiment and equivalent changes made according to the claims of the present invention still fall within the scope of the invention.

Claims

1. A method for preparing a homocysteine ​​detection kit with good stability, characterized in that: The following steps are involved: The pH of the obtained multiple first raw materials is adjusted, and after stirring, standing and filtering, the corresponding second raw materials are added and stirred to obtain the first reagent, specifically: according to the ratio requirements, 100mmol / L of buffer system, preservative and 0.01-0.06g / L of serine are added to the mixing container, and the pH value is adjusted to 9.0±0.2; 10-100mmol / L of reducing agent is added to the mixing container, and the reducing agent concentration refers to the TCEP concentration; the mixing container is stirred at the set stirring time and stirring speed; then, the mixing container after stirring is placed at 2-8 degrees for balance for at least 24h, and filtered with a stainless steel filter and a filter membrane, and finally NADH 0.1-0.5g / L and LDH 10-50KU / L are added to the filtered mixing container for stirring and mixing to obtain the first reagent; wherein the reducing agent is a mixture of TCEP, GPC and EGTA, and the reducing agent mixture is mixed at a molar concentration ratio of 1:0.8-1.2:2-2.5; The pH values ​​of the obtained multiple third raw materials are adjusted to 7.6±0.2, and the corresponding fourth raw materials are added and mixed to obtain the second reagent. Specifically, according to the formula requirements, a buffer system of 50mmol / L, a stabilizer of 1-100g / L, and a preservative are added in sequence to another mixing container, and the pH value is adjusted to 7.60±0.20, and cystathionine β-synthase of 1-10KU / L, cystathionine β-lyase of 1-10KU / L, and an activator of 0.001-0.01g / L are added in sequence to obtain the second reagent.

2. A homocysteine ​​detection kit with good stability prepared by the preparation method of a homocysteine ​​detection kit with good stability as claimed in claim 1, characterized in that: The homocysteine ​​detection kit with good stability comprises a first reagent and a second reagent, wherein the first reagent comprises a first raw material and a second raw material, and the second reagent comprises a third raw material and a fourth raw material; The first raw material includes a buffer system of 100 mmol / L, a preservative and serine of 0.01-0.06 g / L, and a reducing agent of 10-100 mmol / L, wherein the reducing agent concentration refers to the TCEP concentration; the second raw material includes NADH of 0.1-0.5 g / L and LDH of 10-50 KU / L; The third raw material includes a buffer system of 50 mmol / L, a stabilizer of 1-100 g / L, and a preservative; the fourth raw material includes cystathionine β-synthase of 1-10 KU / L, cystathionine β-lyase of 1-10 KU / L, and an activator of 0.001-0.01 g / L; The reducing agent is a mixture of TCEP, GPC, and EGTA, wherein the TCEP, the GPC, and the EGTA are mixed at a molar concentration ratio of 1:0.8-1.2:2-2.

5.

3. The homocysteine ​​detection kit with good stability as claimed in claim 2, characterized in that: The stabilizer is one or more of ethylene glycol, β-methyl dextrin, dextran 70, D-trehalose, and PEG6000.

4. The homocysteine ​​detection kit with good stability as claimed in claim 3, characterized in that: The buffer system is one or more of HEPES, triethanolamine, TRIS-HCL, and TES.